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Abstract
Background: Hospital acquired infections worsen the outcome of patients treated in intensive care units and are
costly. Coatings with silver or metal alloys may reduce or alter the formation of biofilm on invasive medical devices.
An endotracheal tube (ETT) is used to connect the patient to a ventilator and coated tubes have been tested in
relation to bacterial colonization and respiratory infection. In the present study, we aimed to evaluate and compare
a coated and uncoated ETT for patient symptoms and local tracheal tolerability during short term clinical use.
Degree of bacterial colonization was also described.
Methods: A silver-palladium-gold alloy coating (‘Bactiguard®’Infection Protection, BIP) has been extensively used
on urinary tract catheters and lately also on central venous catheters. We performed a randomised, single-blinded,
controlled, first in man, post Conformité Européenne (EC) certification and CE marking study, focused on Bactiguard®
coated ETTs (BIP ETT). Thirty patients at a tertiary university hospital scheduled for upper abdominal elective surgery
with an expected duration of anaesthesia of at least 3 h were randomised; BIP ETT (n = 20) or standard ETT (n = 10).
The tolerability was assessed with a modified version of Quality of Life Head and Neck Module, QLQ-H&N35 and by
inspection of the tracheal mucosa with a fibre-optic bronchoscope before intubation and at extubation. Adverse
Events (AE) and bacterial adherence were also studied. Statistical evaluations were carried out with the Fisher’s Exact
Test, the Clopper-Pearson method, as well as a Proportional Odds Model.
Results: Differences between groups were identified in 2 of 8 patient related symptoms with regard to tolerability by
QLQ-H&N35 (cough, p = 0.022 and dry mouth, p = 0.014 in the treatment group.). No mucosal damage was identified
with bronchoscopy. A low level of bacterial colonization with normal flora, equal between groups, was seen after
short-term of intubation (median 5 h). No serious Adverse Events related to the use of an ETT were observed. The
results should be treated with caution due to statistical confounders, a small study size and large inter-individual
variability in bacterial adhesion.
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Conclusions: The new device BIP ETT is well tolerated and has good clinical performance during short-term
intubation. Studies with larger sample sizes and longer intubation periods (>24 h) in the ICU-setting are needed and
can now be planned in order to identify possible differences in clinical outcomes.
Trial registration: Registered in ClinicalTrials.gov, Registration number: NCT01682486, Date of Registration:
August, 30, 2012
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Background
Hospital acquired infections (HAI) are a global problem
and among the four major causes of death in the Western
world. Generally, 10 % of hospitalised patients in the
Western world acquire HAI [1–4]. Medical devices are
rapidly colonized with bacteria during the formation of
biofilm, which in turn can lead to health care-related in-
fections [5–8]. But as the usage of medical technical
equipment is necessary within the health care system, it is
a particularly important area to study and optimize [9, 10].
To reduce the biofilm formation on endotracheal
tubes, coatings with pure silver or silver compounds
have been evaluated. The efficacy and safety of endo-
tracheal tubes (ETTs) coated with pure silver or silver
compounds have been reported in three randomised
controlled clinical [11–13]. No safety issues were re-
ported. The studies reported significant reduction of bio-
film formation [12, 13] and as well as a delay of VAP.
The noble metal alloy coating has been extensively used
on urinary catheters and central venous lines [14–16].
This is a first in man study on an endotracheal tube with
the Bactiguard® noble metal coating (BIP ETT).
The primary objective was to determine the tolerability
of the medical device BIP ETT compared to standard
uncoated ETTs in a small selected population of patients
undergoing elective surgery. The secondary objective
was to assess the overall safety and performance related
to the medical device. The hypothesis was that the
coated tube (BIP ETT) would be similar to the standard
endotracheal tube with regard to patient-experienced
symptoms and that the tracheal mucosa would be simi-
larly affected by contact with the BIP ETT as by contact
with a standard endotracheal tub. The primary end-
point was patient-reported symptoms in the throat and
mouth, as well as visual appearances of the upper tra-
cheal mucosa the day after tracheal intubation.
Though bacterial colonization is of major interest
when it comes to medical devices inserted in the human
body, this study is focused on the tracheal safety and tol-
erability when exposed to the new coating. Bacterial
colonization after a few hours of endotracheal tube
usage is described here and can be considered as a
baseline in future studies with coated endotracheal tubes
used for longer clinical periods (days).
Methods
Study design
This was a single-centre, randomised, single-blinded,
and controlled, first in man, post Conformity Euro-
permit (EC) certification and CE marking study. Patients
undergoing elective surgery of the upper gastrointes-
tinal tract with an expected duration of at least 3 h
were asked to participate. The study was conducted
at a Karolinska University Hospital in Sweden and
approved by the Ethical Review Board in Stockholm (Dnr
20121205–31, protocol number 1842-2026-CDOC). Writ-
ten informed consent from each patient was obtained
before entry into the study. All patients signed a written
informed consent before participating in the study. The
study is outlined in clinicaltrials.gov database with the
identifier: NCT01682486.
Investigational device BIP ETT
BIP ETT is an endotracheal tube designed for insertion
through the mouth or nose. The, in- and outside sur-
faces are coated with the Bactiguard® coating (Sweden)
which consists of a noble metal alloy of silver, palladium
and gold, which reduces bacterial adhesion in-vitro. The
latter phenomenon is a contributing factor to microbial
colonisation and biofilm formation, which in turn in-
creases the risk for VAP. The BIP ETT is made from
medical grade polyvinyl chloride (PVC). It is a sterile
single use 100 % latex free, two-lumen tube (one lumen
connected to a high volume low pressure cuff with a
standard connector), has a Magill curve and rounded tip
with a Murphy eye.
Control device
Standard uncoated ETTs made of PVC, normally used
for intubation at the investigators site (Mallinckrodt™
ETT) with standard labelling, were used as reference
devices. They were sterile single use 100 % latex free,
two-lumen tubes (one lumen connected to a high
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volume low pressure cuff with a standard connector),
had a Magill curve and rounded tip with a Murphy eye.
Study population
Inclusion criteria were adults ≥18 years of age, requiring
endotracheal intubation ≥3 h needing an endotracheal
tube sized 7 or 8 mm. Exclusion criteria were cognitive
dysfunction (i.e., inability to understand and fill out the
study questionnaires), transmissible blood disease, multi-
resistant bacterial colonization, current or continuous
treatment with immune modulating therapies, e.g., sys-
temic (or inhalation) use of cortisone or non-steroid
anti-inflammatory drugs (NSAID), on-going respiratory
infection, as well as deficient poor skills in writing and
or speaking Swedish.
Screening and randomization
The list of scheduled major surgery eligible patients were
identified and scanned and thereafter screened by read-
ing the patients’ journal. Eligible patients were later
approached for information and consent. In total, 30
patients were screened and 30 patients were enrolled in
the study. The enrolled patients were randomised to air-
way management during anaesthesia and surgery with
either the BIP ETT (n = 20) or standard ETT (n = 10).
The randomisation was designed to distribute the pa-
tients in a ratio of 2:1 in favour of the BIP ETT group.
One patient in the BIP ETT group was prematurely
withdrawn from the study due to vomiting during induc-
tion of anaesthesia. The patient then needed a rapid
sequence induction and therefore, pre-intubation bron-
choscopy could not be carried out. Therefore, the
patient was withdrawn from the study.
Endpoints
Primary endpoints
The difference between the treatments (BIP ETT versus
standard ETT) for each of the 8 questions in the modi-
fied European Organization for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire for
Head & Neck with 35 questions (QLQ H&N35) [18], on
the day after tracheal intubation.
The difference between treatments (BIP ETT versus
standard ETT) in photo assessment (blinded assess-
ment), and direct assessment (unblinded assessment) of
the surface tracheal lining, before intubation and after
extubation.
Secondary endpoints
Safety assessed based on adverse events (AE) and serious
AEs (SAEs) and on any problems occurring during the
post-operative course (Yes/No).
Performance assessed by bacterial colonization of BIP
ETT versus standard ETT, microbiological testing of
bacteria from a defined area of the ETT surface ex vivo
(quantification and typing).
Data collection
Demographics, smoking habits, medical history of sig-
nificance, and concomitant medication were assessed
prior to surgery. The study comprised of four visits; a
telephone contact by a study nurse to inform the patient
about the study and send the written patient information
to the patient up to 28 days prior to screening (Visit 1);
a screening visit 1 to 14 days prior to surgery when also
the informed consent form was signed and demographic
data, medical history gathered and physical examination
was performed (Visit 2); the actual day of surgery/intub-
ation (Visit 3), and a follow-up on the day after surgery
(Visit 4).
The study intervention was carried out at Visit 3. As
the patient arrived in the operating theatre, local rou-
tines were followed. No lidocaine or lubricating jellies
were used in conjunction with the ETT. Prior to intub-
ation of the ETT, the endotracheal cuff was inflated as a
test. The intubation was carried out after a bronchos-
copy where the ETT was pulled over the fiberscope, and
the cuff pressure was kept below 20 cmH2O if possible.
Endotracheal cuff pressures were recorded using an
intra-cuff monitor, and the pressure was recorded during
the anaesthesia. After induction of anaesthesia, the num-
ber of intubation attempts and the need for other intub-
ation devices were recorded, as well as any injuries to
lip, tongue or teeth. The ETT was not to be repositioned
unless necessary. During extubation, a bronchoscope
was again placed in the trachea through the ETT. The
ETT was then removed and the trachea inspected. The
time for intubation and extubation, as well as the type of
fibre-optic bronchoscope were noted. The medical tech-
niques and aseptic procedures used were according to
currently accepted practice.
Assessments of tolerability
To assess the tolerability of the BIP ETT, a modified ver-
sion of the head and neck module of the questionnaire
developed for assessing quality of life was used (Quality
of Life Head and Neck Module, QLQ-H&N35) [18]. The
questionnaire was originally developed by the European
Organization for Research and Treatment of Cancer
(EORTC) [19]. In the present study, eight of the ques-
tions, which assessed symptoms that can occur after in-
tubation, were used. Permission to use the adjusted
version was obtained from EORTC. The selected ques-
tions were the following (the original question number
in the EORTC QLQ H&N35 within parenthesis):
 Have you had pain in your mouth? (31)
 Have you had pain in your jaw? (32)
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 Have you had soreness in your mouth? (33)
 Have you had a painful throat? (34)
 Have you had problems swallowing liquids? (35)
 Have you had a dry mouth? (41)
 Have you coughed? (45)
 Have you been hoarse? (46)
Each patient indicated the extent to which he/she had
experienced these symptoms or problems as “Not at all”,
“A little”, “Quite a bit” or “Very much”. The question-
naire was completed by the patients at 2 time points in
time; prior to surgery (Visit 3, to cover the past 24 h)
and in the morning of the first post-operative day
(Visit 4, to cover the period post-surgery). The base-
line was established before surgery in order to be able
to distinguish between the intensity of symptoms in
relation to the tube alone and not the patient’s condi-
tion prior to surgery.
In order to detect any changes in the tracheal mucosa
correlated with the ETT, visual inspections were carried
out by an anaesthesiologist/surgeon both before intub-
ation and after extubation using a flexible fibre-optic
bronchoscopy. The assessments were formulated using
the following 4-graded scale:
I. No signs of irritation/inflammation of the mucosa in
the trachea
II. Weak signs of irritation/inflammation of the mucosa
in the trachea
III.Clear signs of irritation/inflammation of the mucosa
in the trachea
IV.Extensive signs of irritation or extreme discoloration/
inflammation of the mucosa in the trachea
Assessments of performance and safety
Safety and Performance were assessed after surgery
(Visit 3 and Visit 4) by noting Adverse Events, occur-
rence of complications during the post-operative
course and any ETT handling problems experienced
by the staff. It was the duty and right of the investi-
gator to interrupt the patient’s participation if the
patient’s health or well-being was threatened by con-
tinuation in the study. A patient could be discontin-
ued if e.g., wrong ETT was placed by mistake.
Further, concomitant medications could require a
patient’s discontinuation. However, each case of with-
drawal was to be discussed individually with the
Sponsor prior to any decision of discontinuation,
unless the decision was based on safety reasons. The
pre-defined reasons for patient withdrawal were as
follows:
1. Serious life threatening AE, related or unrelated to
the treatment in test (i.e., the ETT). This could be
events such as critical bleeding, myocardial infarct,
urticaria, angioedema chock and asthma bronchiale.
2. Patient’s own request
3. Investigator’s opinion that it is in the patient’s best
interest to discontinue. The reason, time and date
of discontinuation had to be recorded in the eCRF.
Exploratory assessments of microbial adhesion to
endotracheal tubes
Immediately after extubation, the distal piece of the
ETT was cut with a sterile pair of scissors precisely
above the cuff into a sterile tube containing PBS
(Phosphate Buffered Saline) covering the tube to keep
microorganisms alive. The container was immediately
transported to the Department of Clinical Microbiology,
to assess the quantity and type of pathogen and/or non-
pathogen microbes. The antibiotic resistance of pathogen
microbes (if those were found) was also to be determined.
At arrival in the lab, the tube was vortexed vigorously
in order to remove mucus from the ETT piece. The
ETT piece was then moved to a new tube containing
30 mL of PBS, washed by vortexing and if needed re-
peatedly washed until all visual mucus was removed.
Thereafter it was put in another tube containing 10 mL
PBS and 0.05 % Tween-20. In order to remove the ad-
hered microorganisms from the surface it was vortexed
for 1 min at maximum speed. The PBS-Tween solution
with the removed microorganisms was diluted and
plated out according to standard procedures for clinical
airway sampling at the Dept. of Clinical Microbiology,
and evaluated by viable count and microbiological typing
the following day [20–22].
Statistical analysis
In this exploratory study, 30 patients (20 patients in the
BIP ETT group and 10 in the uncoated, standard ETT
group) were judged to be needed in order to reveal sta-
tistically significant differences in the primary analyses.
With an estimated drop-out rate of 20 %, the expected
number of evaluable patients was 24. At the end, 29
patients were evaluated (19 in the BIP ETT group and
10 in the standard ETT group).
For the 8 questions used from the EORTC QLQ
H&N35, the difference between the treatment groups on
the day after surgery were tested with Fisher’s Exact
Test. Confidence intervals (95 %) of the proportion of
patients for each treatment were calculated using the
Clopper-Pearson method. The questions after surgery
were analysed with a Proportional Odds Model, specify-
ing a multinomial distribution and cumulative logit link.
The model included the answer of the respective ques-
tions before surgery as a covariate, and tested the differ-
ence between the treatments using the likelihood ratio
statistic. The proportional odds assumption was tested
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with the Score test. If more than 4 of the 8 score tests
rejected the null hypothesis of proportional odds, then
an extended Mantel-Haenzel analysis controlling for the
EORTC QLQ H&N35 answer before surgery were to be
applied for each of the questions.
Differences between the treatment groups of assessed
changes in the tracheal mucosa, on the 4-graded scale,
were analysed using Fisher’s Exact Test. Confidence in-
tervals (95 %) of the proportion of patients for each
treatment were calculated using the Clopper-Pearson
method.
Direct assessment after extubation was also to be ana-
lysed using a Proportional Odds Model, including the
evaluation/judgement prior to intubation as a covariate.
However, since all patients in the standard ETT treat-
ment group were in the same category at extubation, the
Proportional Odds Model analysis was not applicable.
Adverse events (AEs) and adverse device related
events (ADEs) were coded using MedDRA version 15.1.
No statistical tests were carried out but an overall sum-
mary of the number and proportion of patients and the
number of events in each AE category (AE, SAE (Serious
AE), ADE, SADE (Serious ADE) was made. However,
since only one AE was reported, no tabulation of AEs/
ADEs was carried out. Problems during the post-
operative course are presented with descriptive statistics
by treatment group (number and proportion of patients).
Problems related to the ETT handling were presented in
descriptive statistics by treatment group as the number
and proportion of patients in each category (Yes/No).
Results
All patients, who had completed the study (n = 29), were
included in the analysis set; n = 19 in BIP ETT treatment
group and n = 10 in the standard ETT treatment group.
Demographics
The demographics, weight and height, are given in
Table 1.
No deviations were found for any of the patients in
either treatment group regarding physical examination
or vital signs prior to surgery. In total, 4 patients in the
study had concurrent diseases or relevant medical
history, see Table 2.
Tolerability evaluation
Modified EORTC QLQ H&N35
Before surgery, none of the patients from either study
group reported any pain in their mouth, jaw or throat,
nor did anyone report any swallowing problems. One
patient in the BIP ETT group reported soreness in the
mouth, 5 %. With regards to cough one case in the BIP
ETT-group (5 %) and in two cases in the control ETT
group (20 %) were reported a substantial number of
patients experienced dry mouth before surgery i.e., 63 %
in BIP ETT group and 50 % in the standard ETT group.
Thus, both groups reported similar symptoms from the
throat area before the surgery.
The difference between responses from the BIP ETT
group and standard ETT group on the day after surgery
was tested using Fisher’s Exact Test. The outcome after
surgery is reported in the Table 3.
A statistically significant difference was found for dry
mouth (p-value: 0.0434), suggesting more problems with
dry mouth in the BIP ETT treatment group. As men-
tioned, a large proportion (63 %) of these patients
reported symptoms before surgery. No statistically sig-
nificant difference was found for the other symptoms/
problems. Fisher’s Exact Test was not carried out for
pain in the jaw and soreness in mouth since all patients
were in the same category.
An analysis with Proportional Odds Models controlled
for value/category prior to surgery for cough and painful
throat symptoms. But due to non-convergence, not
for the value prior to surgery concerning pain in the
jaw and dry mouth. There was a statistically significant
difference between the treatment groups for cough p =
0.022 and for dry mouth symptoms p = 0.014, suggesting
Table 1 Demographics and baseline characteristics
Coated ETT Standard ETT Total p-value
n = 19 n = 10 n = 29
Age Mean (SD) 67.3 (7.3) 60.8 (13.7) 65.1 (10.2) 0.19
Sex Female 13 (68 %) 5 (50 %) 18 (62 %) 0.43
Male 6 (32 %) 5 (50 %) 11 (38 %)
Weight (kg) Mean (SD) 72.1 (16.2) 72.0 (9.7) 72.0 (14.1) 0.98
Height (cm) Mean (SD) 166.7 (8.5) 172.6 (8.5) 168.7 (8.8) 0.09
Smoking Status Never smoked 13 (68 %) 6 (60 %) 19 (66 %) 0.84
Stopped 4 (21 %) 3 (30 %) 7 (24 %)
Yes, currently 2 (10 %) 1 (10 %) 3 (10 %)
Max Maximum, Min Minimum, Q1 First quartile, Q3 Third quartile, SD Standard deviation
Percentages are based on the number of subjects within each treatment group
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somewhat more problems with these aspects in the
BIP ETT treatment group compared to the standard
ETT group, see Table 4. Since more patients in the
BIP ETT group had symptoms prior to surgery,
regarding the dry mouth symptom this difference
should be treated with caution.
There were no signs of irritation or inflammation of
the upper airway surface tracheal lining at intubation or
extubation, in the standard ETT group. In the BIP ETT
group, weak signs of irritation/inflammation were seen
at intubation for one patient (5.6 %). At the time of extu-
bation, 4 patients had weak signs of irritation/inflamma-
tion. In one of the cases, however, − the evaluation prior
to surgery was missing and in a second case, the patient
had showed irritation already prior to surgery. There
was no statistically significant difference between the
BIP ETT and standard ETT treatment group (p-value:
0.268), see Table 5.
Safety and performance evaluation
One AE was reported for one patient in the BIP ETT
group during the course of the study.
A shallow wound was seen in the trachea prior to
extubation, probably caused either by the mechanical
impact of the fiberscope and/or the BIP ETT according
to the anaesthesiologist. It was not considered a result of
a difficult airway hence the patient was not excluded
from the analysis set. No signs of inflammation were
noted. The start date of the event was reported as the
day of surgery (Visit 3), and the event was on-going at
the time of the patient’s study completion. The event
was considered mild in severity and non-serious. No
medication or treatment was given due to the AE.
ETT handling problems were reported for 1 patient
(5 %) in the BIP ETT group: there were some difficulties
when pulling the ETT over the fibreoptic bronchoscope.
This was however not considered serious.
Exploratory assessment of microbial adhesion to
endotracheal tubes
The microbiological analysis of the ETTs after extubation
showed Enterococci species, Haemophilus parainfluenzae,
Neisseria species, Staphylococci and Streptococci species,
see Table 6. These species are all recognized as normal
flora in the airways, i.e., no pathogenic species were found
on either type of ETT. Therefore, no antibiotic resistance
testing was carried out. The level of bacterial colonization
on the ETT surfaces was similar for both ETT types,
approximately 101 to 103 CFU/cm2, see Figs. 1 and 2. Due
to a large inter-patient variation for both tubes, a reduc-
tion of bacterial adhesion of the same magnitude as the
one observed invitro was not possible to detect. As the
Alpha-haemolytic Streptococci and Neisseria species were
the most commonly isolated bacteria from the tubes, they
were plotted/visualized in graphs, see Figs. 1 and 2.
Discussion
This was a single-centre, randomised, single-blinded,
and controlled, first- in- man, post Conformity Euro-
permit (EC) certification and CE marking study. The
study was planned to address a clinical concern that the
tracheal mucosa; known to be one of the bodies most
sensitive and reactive tissue; might be irritated by the
new coating. The tracheal surface is known to react with
coughing, swelling, and irritations to many substances
even in very tiny doses. So therefore, the primary end-
point in this study was; tolerability of the coated tube in
the human trachea.
The major finding in this comparative clinical device-
testing study of coated BIP ETTs and uncoated ETTs,
was that practically no differences in tolerability and per-
formance could be detected during short term use, i.e.,
intubation 3 to 8 h, in patients scheduled for elective
abdominal surgery during general anaesthesia. This
observational first-in-man study had a randomised, single-
blind and controlled design, where standard, uncoated
Table 2 Medical/surgical history and concurrent diseases
Coated ETT Standard ETT Total p-value
n = 19 n = 10 n = 29
System Organ Class/Preferred Term n (%) n (%) n (%)
Immune system disorders 2(10) 1(10) 3(10) 1
Allergy to metals 1 (5) 1(10) 2 (7)
Drug hypersensitivity 1 (5) 0 1 (3)
Seasonal allergy 0 1(10) 1(3)
Respiratory, thoracic and mediastinal disorders 1(5) 0 1(3) 1
Cough 1(5) 0 1(3)
Surgical and medical procedures 0 1(10) 1(3)
Coronary artery bypass 0 1(10) 1(3) 0.34
n = Number of patients reporting the term
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ETTs served as comparator. The primary objective was to
determine the tolerability of the BIP ETT compared to the
standard ETT. Symptoms from mouth, throat and airway
were assessed by questionnaires and the tracheal mucosa
was inspected post exposure. Furthermore, performance
and a few safety aspects related to BIP ETT were assessed
based on reported AEs and adverse device-related events,
as well as problems during the post-operative course, and
ETT handling problems experienced by the health care
personnel.
Tolerability and adverse events
The modified EORTC QLQ H&N35 is comprised of 8
questions pertaining to symptoms/problems from the
ear, nose and throat areas. The questionnaire EORTC
QLQ H&N35 was primarily developed to investigate
health-related quality of life issues in patients with head
and neck cancer and is very well validated and used in
many studies [23, 24]. We chose eight questions as they
covered symptoms that may occur after an intubation.
The frequency of symptoms was as expected an increase
Table 3 Modified EORTC QLQ H&N35. Differences between treatment groups after surgery using the Fisher’s Exact Test
Coated ETT Standard ETT
n = 19 n = 10
Parameter Analysis value n (%) 95 % CIa n (%) 95 % CIa p-valueb
Cough Not at all 9 (47) (24; 71) 7 (70) (35; 93) 0.6294
A little 9 (47) (24; 71) 3 (30) (7; 65)
Quite a bit 0 (0;18) 0 (0; 31)
Very much 1 (5) (0; 26) 0 (0; 31)
Dry mouth Not at all 0 (0; 18) 1 (10) (0; 44) 0.043
A little 0 (0; 18) 2 (20) (2; 56)
Quite a bit 6 (32) (13; 57) 4 (40) (12; 74)
Very much 13 (69) (43; 88) 3 (30) (7; 65)
Hoarse Not at all 5 (26) (9; 51) 2 (20) (2; 56) 0.883
A little 9 (47) (24; 71) 4 (40) (12; 74)
Quite a bit 3 (16) (3; 40) 3 (30) (7; 65)
Very much 2 (10) (1; 33) 1 (10) (0; 44)
Pain in jaw Not at all 19 (100) (82; 100) 10 (100) (69; 100)
A little 0 (0; 18) 0 (0; 31)
Quite a bit 0 (0; 18) 0 (0; 31)
Very much 0 (0; 18) 0 (0; 31)
Pain in mouth Not at all 19 (100) (82; 100) 9 (90) (56; 100) 0.345
A little 0 (0; 18) 1 (10) (0; 44)
Quite a bit 0 (0; 18) 0 (0;31)
Very much 0 (0; 18) 0 (0; 31)
Painful throat Not at all 13 (68) (43; 88) 9 (90) (56; 00) 0.590
A little 5 (26) (9; 51) 1 (10) (0.3; 44)
Quite a bit 1 (5) (0.1; 26) 0 (0; 31)
Very much 0 (0; 18) 0 (0; 31)
Problems swallowing liquids Not at all 19 (100) (82; 100) 8 (89) (52; 100) 0.333
A little 0 (0; 19) 0 (0; 34)
Quite a bit 0 (0; 19) 0 (0; 34)
Very much 0 (0; 19) 1 (11) (0.3; 48)
Soreness in mouth Not at all 19 (100) (82; 100) 10 (100) (69; 100)
A little 0 (0; 18) 0 (0; 31)
Quite a bit 0 (0; 18) 0 (0; 31)
Very much 0 (0; 18) 0 (0; 31)
aConfidence Interval bFisher’s Exact Test
Fisher’s Exact Test was not performed for pain in jaw and soreness in mouth since all patients were in one category
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in both groups, and some differences in cough and dry
mouth was observed. The difference should be treated
with caution because of small study groups in combin-
ation with a statistical model, which could not correct
the differences in baseline (before surgery) due to non-
convergence. No known attributes of the BIP ETT have
been identified that rationally could explain the possibly
increased problems with cough and dry mouth. How-
ever, the design of the two ETTs differed slightly, which
could potentially have played a role.
Further, there was no statistically significant difference
regarding the appearance of the tracheal mucosa be-
tween the 2 treatment groups at extubation. Safety was
also evaluated by AE and ADE incidence and the occur-
rence of any post-operative. No severe AEs were noted
post-operatively in either of the treatment groups.
Microbial assessment
In order to assess microbial adhesion to the ETTs a distal
piece of the ETT was cut off after extubation. The quan-
tity and type of pathogen and non-pathogen bacteria were
assessed. The microbiological testing found Enterococci,
Haemophilus parainfluenzae, Neisseria, Staphylococci, and
Streptococci species, which are species all recognized as
normal flora in the airways [25–27]. No pathogenic spe-
cies were found therefore no antibiotic resistance testing
was carried out.
The level of bacterial colonization on the ETT surfaces
was similar for both types of tubes, approximately 101 to
103 CFU/cm2 and overall low compared to other studies
where the tracheal colonization has been investigated
[25–27]. We found a large inter-patient variation with
regards to microbial adhesion for both types of surfaces
and it is known that the normal flora differs between pa-
tients with regards to both the species found and the
amount of each species. In vitro experiments have
shown significant reduction in adhesion of several spe-
cies, both Gram positive and Gram negative to the
coated BIP ETT, (unpublished data).
The time of intubation in the current study was be-
tween 3 and 8 h, (mean 5 h and 14 min) which is short
when evaluating microbial adherence in vivo. Bacterial
biofilms have been shown to develop on ETTs after
around 24 h, and it is this advanced form of microbial
adhesion and subsequent detachment that play a part in
the development of infection [28]. Further, the definition
of VAP (Ventilator Associated Pneumonia) requires a
time frame of at least 24 of intubation [29]. In conclu-
sion, the used microbial assessments were found easy to
employ, and detected reasonable bacterial colonisation
even after short periods of intubation.
Clinical relevance/importance, study limitations and
future studies
The primary purpose of this study was to establish
whether the noble metal alloy coated BIP ETT could be
well tolerated during short-term (up to 8 h) clinical use
in anaesthesia and elective surgery [30, 31]. This was
considered necessary before further trials of the device
could be carried out in a potentially more complex study
Table 4 Modified EORTC QLQ H&N35 Difference between
treatments day after surgery, Proportional Odds Model
Parameter Odds Ratioa 95 % CIb p-value
Cough 0.082 0.003, 0.726 0.022
Dry mouth 0.14 0.02, 0.67 0.014
Hoarse 1.56 0.38, 6.62 0.535
Painful throat 0.24 0.01, 1.71 0.165
aOdds ratio between coated ETT and standard ETT (ratio of the odds of being
in the lower categories). The model controls for baseline for the parameters
Cough and Painful throat but due to non-convergence, baseline was not
included in the Dry mouth and Hoarseness models. The Proportional Odds
Model was only applied to the symptoms/problems when not all patients
within a treatment group were in the same category
bLikelihood ratio based confidence interval
Table 5 Upper airway unblinded judgement, Fisher’s Exact Test
Coated ETT Standard ETT
n = 19 n = 10
Parameter Analysis value n (%) 95 % CIa n (%) 95 % CIa p-valueb
Intubation I 17 (94) (73, 100) 10 (100) (69 % 100) .
II 1 (6) (0, 27) 0 (0, 31) .
III 0 (0, 19) 0 (0, 31) .
IV 0 (0, 19) 0 (0, 31) .
Extubation I 15 (79) (54, 94) 10 (100) (69, 100) .
II 4 (21) (6, 46) 0 (0, 31) .
III 0 (0, 18) 0 (0, 31) .
IV 0 (0 %, 18 %) 0 (0 %, 31 %) 0.2680
aConfidence intervals calculated using Clopper-Pearson method. bFisher’s Exact Test. Only provided for extubation
I - No signs of irritation/inflammation of the mucosa in the trachea; II - Weak signs of irritation/inflammation of the mucosa in the trachea; III - Clear signs of
irritation/inflammation of the mucosa in the trachea; IV - Extensive signs of irritation or extreme discoloration/inflammation of the mucosa in the trachea
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group consisting of ICU patients, with longer intubation
periods. Knowing the degree of sensitivity in the trachea
a patient centred outcome seemed reasonable. As the
human trachea had not been exposed to the coating be-
fore there was no observation that could be used as a
base for a proper power analysis. We considered an ob-
servational study on at least 16 patients with 8 controls
to be reasonable. As we were eager not to have fewer
observations than that, we screened and included 30
patients expecting a drop-out rate of 20 %. However we
ended up with a drop-out rate of only 3 %. To add an
explanatory measure to eventual patient-experienced
symptoms we performed a pre- and post-intubation
bronchoscopy.
A methodological limitation in the study is that we
intubated the patients after bronchoscopy, using the pre-
viously inserted bronchoscope to guide the tube into the
trachea. This could lead to contamination of the tube
and the trachea with bacteria from the mouth. Despite
the possibility of contamination by the bronchoscope,
the identified bacteria do not appear of clinical rele-
vance. We do not think it has affected our results as the
study was randomized, there was a control group and
the same methodology was used in both groups. Other
limitations of the current study include the small sample
size, uneven treatment group sizes and the short intub-
ation time and unblended inspection of the tracheal
mucosa. Hence, the next step is to carry out a study in a
larger population, with a longer intubation period
(>24 h) and in a patient group during ICU care to enable
evaluation of a possible reduction in VAP.
Conclusions
We compared tolerability and functional performance
between a new, coated endotracheal tube (BIP ETT) and
a standard endotracheal tube (ETT), and found minor
differences during short-term use, 3 to 8 h of intubation.
The differences were observed only in 2 of 8 symp-
toms - in coughing, p = 0.022 and possibly in dry
mouth (p = 0.014, but with presence of statistical con-
founders), while there was no difference in adverse events
and no mucosal damage. The results should be treated
with caution due to a small study size. Further, the current
study had too short intubation periods and too small sam-
ple sizes to detect differences in the reduction of bacterial
adhesion and biofilm formation due to large inter-
individual variability in the results. In summary, the study
shows that the BIP ETT is well tolerated and has good per-
formance. Studies of larger sample sizes and longer intub-
ation periods (>24 h) in the ICU-setting can now be
planned for the evaluation of the possible efficacy of the
BIP ETT in reducing bacterial colonisation and prevention
of VAP.
Key messages
Healthcare associated infections continue to play a major
role in complicating hospital care. The surface of various
devices can be modified in order to reduce bacterial
colonization and subsequent infection. We compared new
surface-coated endotracheal tubes to standard devices
during elective surgery for 3–8 h, and found insignificant
differences in tolerability and performance. Only larger
studies with longer exposure times in special patient pop-
ulations (ICU) could demonstrate possible benefits of the
surface coating in reduction of VAP and produce experi-
ence supporting extrapolation of conclusion on safety
from this limited study into general patient population.
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Fig. 1 In vivo colonization of Streptococcus presented as CFU/cm2.
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Fig. 2 In vivo colonization of Neisseria presented as CFU/cm2.
Standard deviation is displayed
Table 6 Microbiological isolation from endotracheal tubes
Microorganism Coated ETT, Standard ETT,
n = 19 (%) n = 10 (%)
Alpha-hemolytic Streptococcus 18 (95) 10 (100)
Neisseria species 11 (58) 8 (80)
Enterococci species 1 (5) 0 (0)
Haemophilus parainfluenzae 2 (11) 0 (0)
Coagulase-negative Staphylococci 4 (16) 1 (10)
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